Parallel Advisors
EIDX

Parallel Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Parallel Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-172
Closed -$8K – 2820
2020
Q1 		$8K Buy
+172
New +$8.76K ﹤0.01% 1753

Other funds holding EIDX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Parallel Advisors's EIDX Position: Q2 2020 in Review

Parallel Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2020, closing a stake of 172 shares — an estimated $8K sold.

Parallel Advisors first reported a position in EIDX in Q1 2020 and held it in 1 quarter. The position peaked at $8K in Q1 2020. 92 funds tracked by Wall St. Rank hold EIDX as of Q2 2020.

  • Parallel Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Parallel Advisors sold 172 Eidos Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $8K.
  • Parallel Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Parallel Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $8K in Q1 2020.
  • 92 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Parallel Advisors's 13F filing for Q2 2020, filed 16 Jul 2020.